In a series A venture financing round, US-based biotechnology company Affigen has raised $17m to be utilised for advancing the company’s lead programmes in a number of haematological malignancies through pre-clinical validation and into phase I clinical studies.

Black Beret Life Sciences led the financing round on behalf of the company.

Albany Molecular Research (AMRI) Grupo Ferrer Internacional and Accord Healthcare will jointly develop and manufacture a complex parenteral drug product for registration and subsequent commercialisation in the US, under an agreement signed between the former and the latter two companies.

Grupo Ferrer will assist AMRI to develop and provide cGMP manufacturing and analytical support for the new product’s registration, while Accord Healthcare will help advance the product through regulatory submission and commercialisation.

"US-based biopharmaceutical company Bristol-Myers Squibb (BMS) has announced two underwritten public offerings of notes due 27 February 2019 and 27 February 2027."

AMRI and Accord Healthcare are based in the US, whereas Grupo Ferrer is based in Spain.

US-based biopharmaceutical company Bristol-Myers Squibb (BMS) has announced two underwritten public offerings of notes due 27 February 2019 and 27 February 2027, with respective coupon rates of 1.6% and 3.25% to raise gross proceeds of $750m each.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The combined gross proceeds from the two offerings will be $1.5bn, which will be used to fund the company’s share repurchase programme and for general corporate purposes.

Hong Kong-based private equity firm Ally Bridge Group has invested in Swiss-based pharmaceutical company Galenica.

Galencia’s subsidiary, Vifor Pharma, provides pharmaceutical products for the treatment of chronic kidney disease.